Drugs / PACTN
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03258359 | Jan 2018 → Dec 2020 | myelodysplastic syndrome | PersImmune, Inc | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PACTN | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03258359 ↗ |
| Modality | Cell therapy | “This study will evaluate the safety of autologous T cells that have been immunized ex vivo with patient-specific MDS stem cell neoantigens in patients with MDS.” NCT03258359 ↗ |